Hemgenix access in Saudi Arabia

Quick orientation

Hemgenix is the brand name for etranacogene dezaparvovec-drlb, an adeno-associated virus serotype 5 (AAV5) based gene therapy that delivers a codon-optimized Padua variant of the human factor IX gene to liver cells. The U.S. FDA approved Hemgenix on November 22, 2022 for adults with hemophilia B (congenital factor IX deficiency) who currently use factor IX prophylaxis, who have current or historical life-threatening hemorrhage, or who have experienced repeated, serious spontaneous bleeding episodes. The therapy is a single one-time intravenous infusion administered at a CSL Behring certified treatment center under defined pre-treatment screening (AAV5 neutralizing antibody titer, liver function workup) and a multi-year monitoring framework. In Saudi Arabia, KFSH&RC's investment in advanced therapies provides a realistic in-country administration pathway under named-patient coordination. Reserve Meds is the U.S.-side coordinator around that institutional capability. Reserved for you.

Why hemophilia B patients in Saudi Arabia need Hemgenix via NPP

Three structural reasons drive the SFDA Personal Importation Program for Hemgenix. First, Hemgenix is not on the SFDA national drug registration list as a commercially marketed product. Access is gated by named-patient frameworks through institutions that have certified-center capability and a CSL Behring relationship. Second, Hemgenix is not a take-home or self-administered therapy. It is a single one-time intravenous infusion that requires pre-treatment AAV5 neutralizing antibody titer testing (mandatory per the FDA label), liver function workup, screening for hepatitis B and hepatitis C, assessment for active liver disease or significant hepatic fibrosis, and a structured post-infusion monitoring framework that runs for years. Third, even where local payer coverage exists for hemophilia B prophylaxis, national payer engagement with a USD 3.5 million one-time gene therapy is uneven globally, and cash-pay is the practical commercial structure in most cross-border named-patient cases. The clinical case for Hemgenix is patient-specific: lifetime prophylaxis burden, vascular access challenges, adherence considerations, AAV5 antibody status, liver health, and patient preference for a one-time intervention over ongoing infusions.

The Kingdom-specific element is that KFSH&RC, which has invested heavily in cell and gene therapy capability under Vision 2030, is a realistic candidate institution for in-country Hemgenix administration under a CSL Behring certified-center arrangement, subject to that specific institutional-manufacturer relationship being in place for the patient's case. Where the in-country arrangement is not available, the realistic path is travel to a certified center in the U.S., EU, UK, or Canada.

The SFDA Personal Importation Program (PIP) for Hemgenix

The SFDA Personal Importation Program is the regulatory framework that authorizes import of a single Hemgenix dose into the Kingdom for a specific named patient when the receiving facility is a certified center and the treating hemophilia specialist is filing on behalf of that patient. The clinical-justification angle for Hemgenix has five documentable pillars: the hemophilia B diagnosis with factor IX activity confirmation, the current prophylaxis regimen and bleed history that establishes label eligibility, the AAV5 neutralizing antibody titer result with the patient confirmed eligible per the labeled testing requirement, the liver function workup confirming the patient is suitable, and the institutional certified-center sign-off from CSL Behring.

The PIP application contains a clinical justification letter from the treating hematologist addressing the hemophilia B diagnosis with ICD-10 D67, the baseline factor IX activity, the current prophylaxis regimen (recombinant or plasma-derived factor IX with dosing and frequency), the bleed history (annualized bleeding rate, any current or historical life-threatening hemorrhage, repeated serious spontaneous bleeding episodes), the AAV5 neutralizing antibody titer with the patient confirmed eligible, the liver function panel (ALT, AST, alkaline phosphatase, bilirubin) with screening for hepatitis B and hepatitis C, the assessment for active liver disease or significant hepatic fibrosis, and the rationale for one-time gene therapy over continued lifetime prophylaxis. It includes Saudi Commission for Health Specialties (SCFHS) license verification for the prescriber in hematology. It includes the institutional certified-center sign-off documenting readiness to perform the infusion under the FDA-labeled framework and the multi-year post-infusion monitoring including the corticosteroid algorithm for transaminitis. It includes product details (brand Hemgenix, INN etranacogene dezaparvovec-drlb, manufacturer CSL Behring with uniQure as originator, country of origin, dose calculated at 2 x 10^13 genome copies per kilogram body weight, lot, and expiry). And it includes the frozen biologic and GMO-regulated cold-chain plan with continuous temperature logging.

Two PIP-file features deserve attention for Hemgenix. First, the AAV5 neutralizing antibody titer must be measured and documented before the file proceeds. Patients with AAV5 antibody titers above the labeled eligibility threshold are not candidates, and the PIP file requires the laboratory result. Second, the post-infusion corticosteroid algorithm for transaminitis must be documented as the institution's protocol. The FDA label specifies that a tapering oral corticosteroid course is initiated when ALT rises above protocol thresholds, with monitoring through resolution. PIP reviewers expect to see this as the institution's standing protocol, not as an ad-hoc plan.

Approval timelines for Hemgenix at the institutional and SFDA level are not routine. The certified-center capability confirmation and the pre-treatment workup commonly dominate the timeline. The overall arc from first inquiry to infusion is typically 2 to 4 months, with the institutional and clinical workup steps running in parallel with the regulatory filing.

Where Hemgenix gets dispensed in Saudi Arabia

Hemgenix is not dispensed in the conventional sense. It is administered at a CSL Behring certified treatment center after the pre-infusion workup is complete and the dose is calculated against the patient's weight. In the Kingdom, the relevant institutional capability is concentrated in a small number of centers. King Faisal Specialist Hospital and Research Centre (KFSH&RC) in Riyadh is the principal candidate Saudi center for advanced therapies of this class, with established hematology, hepatology, and infusion infrastructure plus the Vision 2030 investment in advanced-therapies capability that supports gene therapy administration. King Abdulaziz Medical City (KAMC) and the broader MNGHA network have advanced hematology programs and are progressively building gene-therapy capacity.

The capability dimensions that matter for Hemgenix administration are: frozen biologic handling at the labeled temperature range, on-site AAV5 antibody titer laboratory or a partnered reference laboratory, hepatology consultation for liver workup and transaminitis management, infusion suite with monitoring capability during and after the infusion, and the multi-year post-infusion durability follow-up framework including serial ALT monitoring with the corticosteroid algorithm and serial factor IX activity measurement. Smaller hospitals do not have this footprint. Patients pursuing Hemgenix in the Kingdom are typically referred to KFSH&RC or to a certified center abroad.

Real cost picture for Hemgenix in Saudi Arabia

The U.S. wholesale acquisition cost for Hemgenix is approximately USD 3.5 million per patient for the single one-time infusion, as set by CSL Behring at launch in late 2022 and reported by Fierce Pharma, Managed Healthcare Executive, and others. This list price established Hemgenix as the highest-priced FDA-approved therapy at the time of launch. The Institute for Clinical and Economic Review (ICER) issued a cost-effectiveness assessment placing a fair price range at roughly USD 2.9 million, below the launched WAC.

For a Saudi case, the cost stack reflects the multi-component reality of a certified-center gene therapy. The drug cost reflects the manufactured Hemgenix product at approximately USD 3,500,000 (approximately SAR 13,125,000 at the SAR 3.75 to USD 1.00 peg). The institutional cost (pre-treatment workup including AAV5 titer and liver panel, the infusion itself, the corticosteroid management for transaminitis, the multi-year monitoring framework with serial ALT and factor IX activity) is set by the certified center and can add USD 50,000 to USD 200,000 (approximately SAR 187,500 to SAR 750,000) depending on workup complexity and any transaminitis management. The frozen-biologic international logistics cost runs in the USD 12,000 to USD 30,000 range per shipment (approximately SAR 45,000 to SAR 112,500), reflecting the validated frozen cold-chain, continuous temperature monitoring, GMO-regulated customs handling for an AAV vector, and the single-dose, single-patient logistics model. Reserve Meds adds a transparent coordination fee per quote.

Bupa Arabia, Tawuniya, and MedGulf Arabia engagement with a USD 3.5 million one-time therapy is typically minimal in the Kingdom. National payer coverage for gene therapies at this price tier is uneven globally; many systems have not built reimbursement pathways for one-time multimillion-dollar therapies. Cash-pay is the practical commercial structure.

Typical timeline for Hemgenix in Saudi Arabia

For a hemophilia B adult patient pursuing Hemgenix through KFSH&RC or a certified center abroad, the typical end-to-end window is 2 to 4 months from first inquiry to infusion. Reserve Meds intake and orientation runs 24 to 48 hours. The pre-treatment workup is the gating sequence: AAV5 neutralizing antibody titer testing (the result either qualifies the patient or rules out gene therapy candidacy entirely), liver function panel, hepatitis B and C screening, and assessment for active liver disease or significant fibrosis. This workup commonly runs 2 to 4 weeks. The institutional certified-center capability confirmation and the CSL Behring relationship verification run in parallel. SFDA PIP filing runs 10 to 21 business days for routine cases and longer for first-time gene therapy filings at the institution. CSL Behring frozen-biologic sourcing and international shipping add 4 to 8 weeks because the per-patient dose-pack is assembled against the confirmed candidate. The single infusion is the gating event; post-infusion monitoring begins immediately with serial ALT checks at defined intervals and the corticosteroid algorithm triggered by transaminitis. Multi-year durability follow-up with serial factor IX activity continues at the certified center, coordinated with local hematology.

What your physician needs to provide

The treating hematologist's clinical justification letter is the foundation. For a Hemgenix case the letter should include the hemophilia B diagnosis with ICD-10 D67 and the baseline factor IX activity, the current prophylaxis regimen with the specific factor IX product and dosing frequency, the bleed history with the annualized bleeding rate and any life-threatening hemorrhage or repeated serious spontaneous bleeding that supports label eligibility, the AAV5 neutralizing antibody titer result with the patient confirmed eligible per the labeled testing requirement (this is mandatory), the liver function panel with screening for hepatitis B and hepatitis C, the assessment for active liver disease or significant hepatic fibrosis, the rationale for one-time gene therapy over continued lifetime prophylaxis, and the planned post-infusion monitoring framework with the corticosteroid algorithm for transaminitis explicitly named.

The letter should explicitly acknowledge that Hemgenix is a single one-time infusion, that there is no repeat administration on the approved label, and that the patient understands the multi-year monitoring commitment including serial ALT checks and serial factor IX activity measurement. The institutional certified-center sign-off is a separate but parallel document; the clinical letter references it. Adverse-event reporting through the SFDA National Pharmacovigilance Center is the prescriber's responsibility throughout the multi-year follow-up window. Long-term durability follow-up is generally measured in years.

Common questions about Hemgenix in Saudi Arabia

Can I receive Hemgenix at KFSH&RC, or do I need to travel? KFSH&RC's investment in advanced-therapies capability under Vision 2030 makes it a realistic candidate institution. Whether your specific case can be administered in-country depends on the institutional certified-center status with CSL Behring at the time of your case, the clinical workup outcome, and the institutional calendar. This is a determination the treating hematologist and the institution make together. Where in-country administration is not feasible, the realistic path is travel to a certified center in the U.S., EU, UK, or Canada.

What is the AAV5 antibody test, and why is it mandatory? Pre-treatment AAV5 neutralizing antibody titer testing is mandatory per the FDA label. Patients with AAV5 antibody titers above the labeled eligibility threshold cannot benefit from AAV5-based gene therapy because pre-existing antibodies neutralize the vector before it can transduce liver cells. The test result either qualifies the patient or rules out gene therapy candidacy entirely. There is no workaround.

What happens if my ALT rises after the infusion? Per the FDA label, transaminase rises are expected in a meaningful fraction of patients and are managed with the label-specified corticosteroid algorithm. A tapering oral corticosteroid course is initiated when ALT rises above protocol thresholds, with monitoring through resolution. The treating hematologist and hepatologist at the certified center own this management. The protocol is built into the institutional standing orders, not improvised case-by-case.

Why Hemgenix versus continued factor IX prophylaxis? Patient and clinician selection is based on bleed history, prophylaxis burden, vascular access, adherence, AAV5 antibody status, liver health, and patient preference for a one-time intervention over ongoing infusions. The HOPE-B phase 3 trial reported a 64% reduction in annualized bleeding rate during months 7 through 18 versus the lead-in period, with 96% of participants free from continuous prophylaxis at 18 months. The treating hemophilia specialist owns this decision. Reserve Meds does not advise on it.

Is there an alternative gene therapy for hemophilia B? Pfizer's fidanacogene elaparvovec (Beqvez) was approved by FDA in April 2024 as a second hemophilia B gene therapy. The treating specialist makes the comparative selection.

Will Bupa Arabia or Tawuniya cover this? At Hemgenix's price point, insurer engagement with a USD 3.5 million one-time gene therapy in the Kingdom is typically minimal. Each plan engages case-by-case. Cash-pay is the practical commercial structure for cross-border named-patient gene therapy access.

Where Reserve Meds fits in Hemgenix cases

Reserve Meds is the U.S.-side concierge coordinator. For a Hemgenix case in Saudi Arabia, Reserve Meds confirms eligibility orientation within 24 to 48 hours, supports the treating hematologist's outreach to KFSH&RC or to a certified center abroad, coordinates documentation flow including the AAV5 antibody titer result and the liver workup, and assigns a single named Concierge Patient Coordinator with Arabic-language support who stays with the patient and family across the multi-month arc and into the multi-year follow-up window. Reserve Meds does not administer Hemgenix, does not perform the pre-treatment workup, does not handle the frozen-biologic shipment directly (that is CSL Behring's coordinated certified-center logistics chain), and does not act as a clinical decision-maker. The clinical authority remains with the treating hemophilia specialist. The regulatory authority remains with SFDA. The administration authority remains with the certified center. Reserve Meds is the connective tissue, with particular value in the upstream patient and family orientation around the AAV5 testing reality, the one-time-only nature of the infusion, the cost envelope, and the multi-year monitoring commitment.

Next step

If you or a family member has hemophilia B and the treating hemophilia specialist has discussed gene therapy, the waitlist is the entry point. Reserve Meds responds within 24 to 48 hours with orientation materials for your hematologist, a framework for the pre-treatment workup including AAV5 antibody titer testing, and an indicative cost range. The realistic timeline and firm quote follow after the institutional certified-center determination and the workup results.

Join the Hemgenix waitlist for Saudi Arabia

Reserved for you.